【摘要】 替考拉宁是治疗耐甲氧西林金黄色葡萄球菌(MRSA)的主要药物之一，在临床上应用广泛。替考拉宁由于特殊的药动学特点，在不同人群的血药浓度变化差异大，可能导致治疗失败或不耐受。进行替考拉宁治疗药物监测(TDM)可以指导临床个体化治疗，确保药物治疗安全、有效。为推进国内替考拉宁TDM实施的规范化，该共识专家组围绕替考拉宁TDM目标、实施方法和个体化给药方案等相关问题进行讨论，最终基于循证证据和专家经验达成共识，以期为医疗机构医师、护士、临床药师以及检测技术人员开展相关工作提供参考。更多还原

【Abstract】 Teicoplanin, a primary drug for the treatment of methicillin resistant Staphylococcus aureus(MRSA), is widely used in clinical practice. Due to its special pharmacokinetic characteristics, teicoplanin exhibits significant variability in blood concentration levels across different populations, which may lead to treatment failure or intolerance. Therapeutic drug monitoring(TDM) for teicoplanin can guide individualized clinical treatment, and ensure the safety and efficacy of drug therapy. In order to advance the standardization of TDM for teicoplanin in China, the expert panel of the consensus discussed relevant issues including TDM objectives, implementation methods and individualized dosing regimens. Based on evidence-based research and expert experience, the consensus was finally formulated to provide references for clinicians, nurses, clinical pharmacists and laboratory technicians in healthcare institutions to conduct related work.更多还原